

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Fahrig, et al.

Serial No.: National State Filing of PCT/EP00/08890

Filed: herewith

For: Use of Substituted 4-Biarylbutyric and 5-Biarylpentanoic Acid Derivatives for the Treatment of Multiple Sclerosis

BOX PCT  
ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING OF FIRST OFFICE ACTION (37 C.F.R. 1.97(b))**

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying copy of PTO form 1449.

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement transmitted herewith is being filed **before** the mailing date of the first Office action on the merits.

**FEE PAYMENT**


Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Reg. No. 31,018

Telephone: (203) 812-2712

Date: 21 March '02

  
\_\_\_\_\_  
William F. Gray  
Attorney for Applicant(s)  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516